top of page

News & Insights 

The AMRN story - Value of U.S. Biopharma Patents

The $AMRN/Vascepa story...

A sad 🥲

but insightful🤔

story about the value of U.S. biopharma patents


From ~$23/share to ~$1/share

in ~5 yrs


Vascepa - the "good" fatty acid in fish oil

• Approved for 2 indications

⇨ Pts with very high blood trigs

⇨ Cardiovascular risk reduction

• Existing U.S. patents cover Indication 2 and mfg method


📅 Fall 2018

• Vascepa Reduce-It Ph3 cardiovascular risk results

• Landmark cardiovascular risk Study

$$$$AMRN ~$23/share


📅 2020/21

• U.S. Composition patents killed

• Vascepa goes generic in U.S.

• Vascepa approved in EP

⇨ + EP exclusivity & EP comp patents

$$AMRN ~$4.50/share


📅 Q1 2023 Vascepa European sales

• $0.8M


📅 7/28/23

~$140M = Enterprise Value

$AMRN 1.19/share


Lots more patent yada yada

to the AMRN story

Could be called the AMRN patent trap

• Method patent protection

For lead indication

but...

• No composition patent protection

• No FDA exclusivity

• An approved, but unpatented indication

• Generics with "skinny" labels

• Induced vs. direct infringement

Maybe I'll provide a detailed article later🤔


In the meantime...

If you want to read more about the AMRN story

from an investor perspective:

Check out my and BiopharmIQ's AMRN tweet string:



 


Want to get notified about our future posts with patent law insights and patent prosecution and clearance process excellence? Sign up for our email list today.


Post History:

07/30/23 posted (EJV)


This blog post is not legal advice and does not necessarily represent the viewpoint of any of the clients of Double Helix Law. Please seek the guidance of a registered and licensed patent attorney or patent agent for any patent-related questions you have. Please note, especially regarding statements made for jurisdictions outside the U.S., that the authors of this article are U.S. patent practitioners.

Comments


Get the latest DHL news and life science patent and investor insights right in your mailbox!

Thanks for subscribing!

bottom of page